Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Levamisole (LMS) was given to stage III gastric cancer patients starting three days before gastrectomy, at a does of 150 mg/day for three consecutive days every other week. Survival rates of these patients were compared with those of stage III gastric cancer patients previously operated in our Department who had not received levamisole. The background factors of both groups were matched as closely as possible. Both groups were concomitantly treated with mitomycin C and FT-207. The survival rate of the LMS group was significantly higher than that of the control group when the tumor had a diameter of 4.0-8.0 cm, cancer cells infiltrated to the gastric serosa, there were metastases within the regional lymph nodes, cancer cells slightly invaded the venous capillaren and there was moderate infiltration of the stroma.
 ...
PMID:Immunochemotherapy with levamisole for stage III gastric cancer patients. 642 Oct 90

This study was conducted in patients with stage III gastric cancer who were admitted and gastrectomized in our Department of Surgery during July 1971 to March 1980. The control group consisted of 32 patients who were treated with mitomycin C and FT -207 during the first half of the period and the levamisole (LMS) group of 32 patients who were treated with the same regimen plus LMS during the latter half of the period. No significant statistical difference in their back ground factors was found. The LMS group was treated with 150 mg/day of LMS for 3 consecutive days every other week starting 3 days before operation. The follow-up study up to 30 postoperative months indicated an enhancing effect of LMS on the survival rate in patients with gastric cancer stage III undergoing curative resection. LMS proved to be effective on inhibition of the tumor growth when the tumor sizes ranged 4.0 to 7.9 cm, and the metastases were limited within the regional lymph node.
 ...
PMID:[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III]. 682 Aug 82

The authors conducted a retrospective review of 234 bone scans of stomach cancer patients who had been diagnosed at the Seoul National University Hospital. In 106 of the 234 cases (45.3%), there were abnormal bone scan results, suggestive of bone metastases. The most common site of bone metastases was the spine, followed by the ribs, pelvis, femur, and skull. These sites were similar to those known for other malignant diseases. The incidence of bone metastases increased according to the duration of disease, especially within 12 months after diagnosis in patients with stage III gastric cancer. The incidence of bone metastases increased as the clinical stage increased. However, the incidence of metastases did not relate to gastric cancer pathologic type. The authors found 6 cases of "superscan" in the 234 bone scans (2.6%). The bone scan findings correlated positively with the level of serum alkaline phosphatase.
 ...
PMID:Evaluation of bone metastases by Tc-99m MDP imaging in patients with stomach cancer. 778 86

The report discusses a method of long-term catheterization of the celiac artery by lumbo-transaortal access. Intraarterial regional chemotherapy with 5-fluorouracil was administered to 56 cases of gastric cancer, stage III, before and after surgery. A significant drop in postoperative complication rate from 47.8 +/- 6% after surgery to 16.0 +/- 4% after combination treatment was recorded. During two years after operation, metastases and recurrences were registered in II out of 52 patients receiving intraarterial chemotherapy (21. +/- 5%), as compared with 34 out of 58 (58.6 +/- 6%) in controls without chemotherapy.
 ...
PMID:[Intra-arterial regional chemotherapy in the combined treatment of stage-III cancer of the stomach]. 807 74

Gastrectomy with D2 lymph node dissection has become the global standard procedure for locally advanced gastric cancer to maximally reduce locoregional recurrence. In East Asia, based on the evidence of the ACTS-GC and the CLASSIC trials, postadjuvant chemotherapy with S-1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the current standard strategy. However, approximately 20% to 30% of patients still develop distant recurrence even after these postadjuvant chemotherapies, especially in those with pathological stage III disease. This review summarizes recent (2008-2018) evidence on the benefits of adjuvant therapy for locally advanced gastric cancer. JACRO GC-07, a Phase III trial, recently showed a superior 3-year recurrence-free survival of the S-1 plus docetaxel regimen in comparison to S-1 monotherapy for patients with pathological stage III gastric cancer after curative D2 gastrectomy. With regard to recent new evidence on neoadjuvant strategy, JCOG0501, a Phase III trial, did not show any superiority in 3-year overall survival (OS) of additional neoadjuvant chemotherapy with S-1/cisplatin over postadjuvant S-1 monotherapy in scirrhous type gastric cancer. Further clinical trials of neoadjuvant chemotherapy are ongoing to improve the poor prognosis for gastric cancer with extensive lymph node metastases. These trials could lead to new evidence for improved treatment of gastric cancer in the near future.
 ...
PMID:Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. 3046 Mar 42